drugset / Trial / NCT05667155
Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To study the safety and efficacy of cord blood-derived CAR-NK cells targeting CD19/CD70 in patients with B-cell non-Hodgkin's lymphoma
Timeline
- Start
- 2022-12-15
- Primary completion
- 2025-01-01
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB dualCAR-NK19/70 | Cell therapy | 2 cells/kg | Intravenous |
| Subject | CB dualCAR-NK19/70 | Cell therapy | 4 cells/kg | Intravenous |
| Subject | CB dualCAR-NK19/70 | Cell therapy | 8 cells/kg | Intravenous |